AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18523643 — intervention group
Group type: COMPARATOR
Intervention: placebo (killed oral Escherichia coli K12)
Number of subjects: 201
Study 15841627 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐Caine Peel
Number of subjects: 30
Study 15841627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15543446 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual obstacle training
Number of subjects: 20
Study 15543446 — intervention group
Group type: COMPARATOR
Intervention: Real obstacle training
Number of subjects: 20
Study 15543446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training methods
Number of subjects: 20
Study 10872536 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogue insulin aspart (IAsp) administered 15 min after the meal (IAsp(+15min))
Number of subjects: 20
Study 10872536 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin (HI) administered immediately before the meal (HI(0min))
Number of subjects: 20
Study 10872536 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogue insulin aspart (IAsp) administered immediately before the meal (IAsp(0min))
Number of subjects: 20
Study 10872536 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin (HI) administered 15 min before the meal (HI(-15min))
Number of subjects: 20
Study 9117225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist triptorelin for 3 months before radical prostatectomy (group I)
Number of subjects: 38
Study 9117225 — intervention group
Group type: COMPARATOR
Intervention: No prior therapy (group II)
Number of subjects: 38
Study 9117225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 8399863 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin/primaquine
Number of subjects: 65
Study 8399863 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMZ
Number of subjects: 65
Study 3947710 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (300 mg/day)
Number of subjects: 0
Study 3947710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3244786 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 3244786 — intervention group
Group type: COMPARATOR
Intervention: Anesthetic therapy with isoflurane
Number of subjects: 0
Study 30501974 — intervention group
Group type: EXPERIMENTAL
Intervention: 1·1 GBq radioactive iodine ablation
Number of subjects: 438
Study 30501974 — intervention group
Group type: COMPARATOR
Intervention: 3·7 GBq radioactive iodine ablation
Number of subjects: 438
Study 30501974 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation with rhTSH
Number of subjects: 438
Study 30501974 — intervention group
Group type: COMPARATOR
Intervention: Preparation with thyroid hormone withdrawal
Number of subjects: 438
Study 29087285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 grams 24 hours and 2 hours preoperatively, 1 gram twice daily for five days post-surgery)
Number of subjects: 100
Study 29087285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ascorbic acid)
Number of subjects: 100
Study 29087285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid group
Number of subjects: 100
Study 29087285 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 29087285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 26040627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with low calorie meal
Number of subjects: 12
Study 26040627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with high calorie meal
Number of subjects: 12
Study 26040627 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low calorie meal
Number of subjects: 12
Study 26040627 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high calorie meal
Number of subjects: 12
Study 26040627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with low calorie meal (duodenum)
Number of subjects: 12
Study 26040627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with high calorie meal (duodenum)
Number of subjects: 12
Study 26040627 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low calorie meal (duodenum)
Number of subjects: 12
Study 26040627 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high calorie meal (duodenum)
Number of subjects: 12
Study 26040627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with low calorie meal (absolute AUC)
Number of subjects: 12
Study 26040627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with high calorie meal (absolute AUC)
Number of subjects: 12
Study 26040627 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low calorie meal (absolute AUC)
Number of subjects: 12
Study 26040627 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high calorie meal (absolute AUC)
Number of subjects: 12
Study 22974480 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenghuan disposable device (Yan's method)
Number of subjects: 120
Study 22974480 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenghuan disposable device (Peng's method)
Number of subjects: 120
Study 22974480 — intervention group
Group type: COMPARATOR
Intervention: Conventional scalpel/suture technique
Number of subjects: 120
Study 21656472 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection
Number of subjects: 70
Study 21656472 — intervention group
Group type: COMPARATOR
Intervention: Sterile water injection (Control)
Number of subjects: 70
Study 19351224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase (4.5 mg in 100-cc physiological solution)
Number of subjects: 38
Study 19351224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological solution)
Number of subjects: 38
Study 16761193 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (300 microg bolus)
Number of subjects: 22
Study 16761193 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional medication)
Number of subjects: 22
Study 14993085 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 3050
Study 14993085 — intervention group
Group type: EXPERIMENTAL
Intervention: Autodialer (automated telephone or mail reminder recall)
Number of subjects: 3050
Study 14993085 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach (in‐person telephone, mail, or home visit recall)
Number of subjects: 3050
Study 14993085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (autodialer with outreach backup)
Number of subjects: 3050
Study 11564911 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg body mass)
Number of subjects: 11
Study 11564911 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free solution
Number of subjects: 11
Study 9426358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure carbohydrate meal
Number of subjects: 16
Study 9426358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure fat meal
Number of subjects: 16
Study 9426358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (carbohydrate, fat, and protein)
Number of subjects: 16
Study 8500311 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention and use of an inhaled bronchodilator
Number of subjects: 6000
Study 8500311 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6000
Study 3326025 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque (iohexol)
Number of subjects: 50
Study 3326025 — intervention group
Group type: COMPARATOR
Intervention: Ultravist-300 (iopromide)
Number of subjects: 50
Study 29908290 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-gauge syringe needle irrigation (SNI)
Number of subjects: 38
Study 29908290 — intervention group
Group type: EXPERIMENTAL
Intervention: EDDY (sonic-powered irrigation system)
Number of subjects: 38
Study 29908290 — intervention group
Group type: COMPARATOR
Intervention: Positive control (no irrigation)
Number of subjects: 38
Study 27051670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 50 mg/d for 12 weeks
Number of subjects: 33
Study 27051670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23659494 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g/day) + Vitamin E (400 IU/day)
Number of subjects: 120
Study 23659494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22970896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency lithotripsy (60 pulses per min)
Number of subjects: 154
Study 22970896 — intervention group
Group type: COMPARATOR
Intervention: High frequency lithotripsy (80 pulses per min)
Number of subjects: 154
Study 20483811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanarkshire Oximetry Index (LOI) cut-off value <0.9
Number of subjects: 161
Study 20483811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanarkshire Oximetry Index (LOI) cut-off value <0.8
Number of subjects: 161
Study 20483811 — intervention group
Group type: COMPARATOR
Intervention: Ankle‐Brachial Index (ABI)
Number of subjects: 161
Study 18825652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0
Study 18825652 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study 16649826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatologic Precautions (DP)
Number of subjects: 1175
Study 16649826 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Precautions (UCP)
Number of subjects: 1175
Study 16649826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (added to existing therapy)
Number of subjects: 1175
Study 14663655 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine or donepezil (acetylcholinesterase inhibitors)
Number of subjects: 35
Study 14663655 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study 11783240 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinggan Jiedu Sanjie Decoction
Number of subjects: 110
Study 11783240 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 110
Study 8546117 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (oral and transdermal)
Number of subjects: 277
Study 8546117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy
Number of subjects: 277
Study 8546117 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy
Number of subjects: 277
Study 8546117 — intervention group
Group type: COMPARATOR
Intervention: Upper body fat distribution
Number of subjects: 277
Study 1930358 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline malate (Stimol, CAS 54940‐97‐5)
Number of subjects: 0
Study 1930358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7173304 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release indomethacin tablet
Number of subjects: 30
Study 7173304 — intervention group
Group type: COMPARATOR
Intervention: conventional indomethacin capsule
Number of subjects: 30
Study 29862649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) after 6 months
Number of subjects: 259
Study 29862649 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) of insulin
Number of subjects: 259
Study 29862649 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to CSII therapy
Number of subjects: 259
Study 27176493 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Ahead group (6-session cognitive-behavioral program)
Number of subjects: 59
Study 27176493 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 59
Study 25440307 — intervention group
Group type: EXPERIMENTAL
Intervention: Child- and family-focused cognitive-behavioral therapy (CFF-CBT)
Number of subjects: 69
Study 25440307 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy as usual (control)
Number of subjects: 69
Study 23224387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenoid positioning system group (patient-specific instrumentation with 3D CT scan planning)
Number of subjects: 31
Study 23224387 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical group (conventional CT scan and surgical technique)
Number of subjects: 31
Study 23224387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenoid positioning system group (for patients with retroversion > 16°)
Number of subjects: 31
Study 23224387 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical group (for patients with retroversion > 16°)
Number of subjects: 31
Study 19749006 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 50
Study 19749006 — intervention group
Group type: COMPARATOR
Intervention: High-flow oxygen mask (Control)
Number of subjects: 50
Study 18507735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DEX) at 480 mg/day for 5 weeks
Number of subjects: 40
Study 18507735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18507735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DEX)
Number of subjects: 40
Study 15638900 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 3621
Study 15638900 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 3621
Study 15638900 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (both doses pooled)
Number of subjects: 3621
Study 15638900 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (extension study)
Number of subjects: 3621
Study 15638900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3621
Study 11856090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily, clarithromycin 250 mg twice daily, and metronidazole 500 mg twice daily (LCM group)
Number of subjects: 134
Study 11856090 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily (LCA group)
Number of subjects: 134
Study 11856090 — intervention group
Group type: COMPARATOR
Intervention: LCA group
Number of subjects: 134
Study 11856090 — intervention group
Group type: EXPERIMENTAL
Intervention: LCM group
Number of subjects: 134
Study 10208193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (42 microg qid) and albuterol sulfate (240 microg qid)
Number of subjects: 1067
Study 10208193 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (36 microg qid)
Number of subjects: 1067
Study 10208193 — intervention group
Group type: COMPARATOR
Intervention: Albuterol base (180 microg qid)
Number of subjects: 1067
Study 8581377 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at doses of 1, 3, or 5 micrograms/kg body weight during concomitantly applied subcutaneous IL‐2 treatment
Number of subjects: 0
Study 8581377 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at doses of 3 and 5 micrograms/kg
Number of subjects: 0
Study 8581377 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2
Number of subjects: 0
Study 2564912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podofilox applied by patients to their own genital warts in up to four treatment cycles
Number of subjects: 109
Study 2564912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podofilox
Number of subjects: 109
Study 2564912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 2564912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study 1052 — intervention group
Group type: EXPERIMENTAL
Intervention: timepidium-bromide
Number of subjects: 101
Study 1052 — intervention group
Group type: EXPERIMENTAL
Intervention: hyoscine-N-butylbromide
Number of subjects: 101
Study 1052 — intervention group
Group type: EXPERIMENTAL
Intervention: prifinium-bromide
Number of subjects: 101
Study 1052 — intervention group
Group type: COMPARATOR
Intervention: placebo (physiological saline solution)
Number of subjects: 101
Study 30753539 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Vector Management (IVM) including community awareness, education, source reduction, larviciding, and mass trapping with autocidal gravid ovitraps (AGO)
Number of subjects: 61511
Study 27283007 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental area of late gadolinium-enhancement (SEE)
Number of subjects: 164
Study 27283007 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (not assessable in 25% of patients)
Number of subjects: 164
Study 27283007 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature tracking-derived circumferential strain (Ecc)
Number of subjects: 164
Study 27283007 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of myocardial injury (MSI)
Number of subjects: 164
Study 24837544 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-FIVES group (skills training program)
Number of subjects: 240
Study 24837544 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information about VA Caregiver Support Services Program)
Number of subjects: 240
Study 22118824 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2248
Study 22118824 — intervention group
Group type: COMPARATOR
Intervention: No Warfarin (Control)
Number of subjects: 2248
Study 20688020 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 3 ml of 0.5% bupivacaine for 5 minutes
Number of subjects: 46
Study 20688020 — intervention group
Group type: COMPARATOR
Intervention: No local anaesthetic (control)
Number of subjects: 46
Study 19067373 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat
Number of subjects: 30
Study 19067373 — intervention group
Group type: COMPARATOR
Intervention: No miglustat treatment (Control)
Number of subjects: 30
Study 16190480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 494
Study 16190480 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 494
Study 12867383 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy at a drug dose of 6 mg/m(2) body surface area and a light dose of 50 J/cm(2)
Number of subjects: 60
Study 12867383 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment with placebo infusion and light exposure
Number of subjects: 60
Study 12867383 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 60
Study 10344660 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of atovaquone (7 daily doses)
Number of subjects: 16
Study 10344660 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of atovaquone (single dose)
Number of subjects: 16
Study 10344660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1824651 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dose at 3 years, 5.2 mg/day)
Number of subjects: 164
Study 1824651 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (mean dose, 66.4 mg/day)
Number of subjects: 164
Study 6346595 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg ALG administered daily for 10 days by intravenous infusion
Number of subjects: 173
Study 6346595 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for 10 days by intravenous infusion
Number of subjects: 173
Study 6346595 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 173
Study 6346595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 6346595 — intervention group
Group type: EXPERIMENTAL
Intervention: Live donor grafts
Number of subjects: 173
Study 6346595 — intervention group
Group type: EXPERIMENTAL
Intervention: Least donor‐recipient histocompatibility mismatches
Number of subjects: 173
Study 30944136 — intervention group
Group type: EXPERIMENTAL
Intervention: Off pump injectable pulmonary valve replacement
Number of subjects: 0
Study 30944136 — intervention group
Group type: COMPARATOR
Intervention: On pump conventional pulmonary valve replacement
Number of subjects: 0
Study 28464426 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative behavioral/pelvic floor exercise intervention + MUS
Number of subjects: 0
Study 28464426 — intervention group
Group type: COMPARATOR
Intervention: MUS alone
Number of subjects: 0
Study 26847748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery with cardiopulmonary bypass
Number of subjects: 95
Study 24451146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen +/− octreotide
Number of subjects: 667
Study 23241359 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 gm/day for 6 weeks
Number of subjects: 120
Study 23241359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pectin 1 gm/day for 6 weeks)
Number of subjects: 120
Study 20002638 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevelle SILK (hyaluronic acid with lidocaine)
Number of subjects: 45
Study 20002638 — intervention group
Group type: COMPARATOR
Intervention: Captique (hyaluronic acid without lidocaine)
Number of subjects: 45
Study 17547890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐cholesterol low‐saturated fat diet (n = 141)
Number of subjects: 290
Study 17547890 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control subjects; n = 149)
Number of subjects: 290
Study 16295781 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 4 g/m2 plus lenograstim (arm A)
Number of subjects: 27
Study 16295781 — intervention group
Group type: COMPARATOR
Intervention: CY 1.5 g/m2 plus lenograstim (arm B)
Number of subjects: 27
Study 12450894 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (specifics not provided)
Number of subjects: 2069
Study 12450894 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee and alcohol consumption (decrease recommended for women)
Number of subjects: 2069
Study 12450894 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity, dietary fiber, and folate intake (increase recommended for men)
Number of subjects: 2069
Study 9783933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284